NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and ...

Galectin Therapeutics Inc.’s GALT share price has dipped by 20.00%, which has investors questioning if this is right time to ...

Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics (GALT), said “In the U.S. approximately 5 million adults are ...

Galectin Therapeutics (NASDAQ:GALT – Get Free Report)‘s stock had its “neutral” rating reissued by equities research analysts at HC Wainwright in a research report issued to clients and investors on ...

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs ...

Here is how ANI Pharmaceuticals (ANIP) and Galectin Therapeutics Inc. (GALT) have performed compared to their sector so far this year.

An institutional investor recently raised its position in Galectin Therapeutics stock. Bank of America Corp DE raised its holdings in Galectin Therapeutics Inc. (NASDAQ:GALT – Free Report ...

NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results ...